Master Alliance Provisions Guide (MAPGuide)

Search Results For:

  • Search results for:
    • CEPI - Novavax, COVID-19 Vaccine Funding Agreement
(Click + to show provisions)
Agreement title
Effective date
Partner type
Technology
Development stage

				GHIAA2019\MapguideSearch Object
(
    [search_parameters] => Array
        (
            [qs] =>  CEPI - Novavax, COVID-19 Vaccine Funding Agreement
        )

    [filters] => Array
        (
            [text_search] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
        )

    [child_filters] => Array
        (
        )

    [agreement_args] => 
    [provision_args] => Array
        (
            [post_type] => provision_document
            [posts_per_page] => -1
            [post__in] => Array
                (
                    [0] => 4205
                    [1] => 4204
                    [2] => 4201
                    [3] => 4200
                    [4] => 3493
                    [5] => 2909
                    [6] => 2908
                    [7] => 2907
                    [8] => 2893
                    [9] => 2892
                    [10] => 2890
                    [11] => 2889
                    [12] => 2885
                    [13] => 4205
                    [14] => 4204
                    [15] => 4201
                    [16] => 4200
                    [17] => 3493
                    [18] => 2909
                    [19] => 2908
                    [20] => 2907
                    [21] => 2893
                    [22] => 2892
                    [23] => 2890
                    [24] => 2889
                    [25] => 2885
                    [26] => 4661
                    [27] => 4147
                    [28] => 4148
                    [29] => 4161
                    [30] => 4159
                    [31] => 4158
                    [32] => 4157
                    [33] => 4156
                    [34] => 4155
                    [35] => 4154
                    [36] => 4153
                    [37] => 4152
                    [38] => 4151
                    [39] => 4150
                    [40] => 4149
                    [41] => 4146
                    [42] => 3812
                    [43] => 3810
                    [44] => 3809
                    [45] => 3808
                    [46] => 3807
                    [47] => 3806
                    [48] => 3805
                    [49] => 3804
                    [50] => 3803
                    [51] => 3802
                    [52] => 3801
                    [53] => 3799
                    [54] => 3798
                    [55] => 3797
                    [56] => 3796
                )

        )

    [text_agreement_args] => Array
        (
            [post_type] => agreement
            [posts_per_page] => -1
            [s] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
        )

    [text_provision_args] => Array
        (
            [post_type] => provision_document
            [posts_per_page] => -1
            [s] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
        )

    [agreement_ids] => Array
        (
        )

    [agreement_q_rslts] => 
    [provision_q_rslts] => 
    [text_agreement_q_rslts] => WP_Query Object
        (
            [query] => Array
                (
                    [post_type] => agreement
                    [posts_per_page] => -1
                    [s] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                )

            [query_vars] => Array
                (
                    [post_type] => agreement
                    [posts_per_page] => -1
                    [s] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                    [error] => 
                    [m] => 
                    [p] => 0
                    [post_parent] => 
                    [subpost] => 
                    [subpost_id] => 
                    [attachment] => 
                    [attachment_id] => 0
                    [name] => 
                    [pagename] => 
                    [page_id] => 0
                    [second] => 
                    [minute] => 
                    [hour] => 
                    [day] => 0
                    [monthnum] => 0
                    [year] => 0
                    [w] => 0
                    [category_name] => 
                    [tag] => 
                    [cat] => 
                    [tag_id] => 
                    [author] => 
                    [author_name] => 
                    [feed] => 
                    [tb] => 
                    [paged] => 0
                    [meta_key] => 
                    [meta_value] => 
                    [preview] => 
                    [sentence] => 
                    [title] => 
                    [fields] => 
                    [menu_order] => 
                    [embed] => 
                    [category__in] => Array
                        (
                        )

                    [category__not_in] => Array
                        (
                        )

                    [category__and] => Array
                        (
                        )

                    [post__in] => Array
                        (
                        )

                    [post__not_in] => Array
                        (
                        )

                    [post_name__in] => Array
                        (
                        )

                    [tag__in] => Array
                        (
                        )

                    [tag__not_in] => Array
                        (
                        )

                    [tag__and] => Array
                        (
                        )

                    [tag_slug__in] => Array
                        (
                        )

                    [tag_slug__and] => Array
                        (
                        )

                    [post_parent__in] => Array
                        (
                        )

                    [post_parent__not_in] => Array
                        (
                        )

                    [author__in] => Array
                        (
                        )

                    [author__not_in] => Array
                        (
                        )

                    [orderby] => title
                    [order] => ASC
                    [suppress_filters] => 
                    [ignore_sticky_posts] => 
                    [cache_results] => 1
                    [update_post_term_cache] => 1
                    [lazy_load_term_meta] => 1
                    [update_post_meta_cache] => 1
                    [nopaging] => 1
                    [comments_per_page] => 50
                    [no_found_rows] => 
                    [search_terms_count] => 7
                    [search_terms] => Array
                        (
                            [0] => CEPI
                            [1] => Novavax
                            [2] => COVID-19
                            [3] => Vaccine
                            [4] => Funding
                            [5] => Agreement
                        )

                    [search_orderby_title] => Array
                        (
                            [0] => wpry_posts.post_title LIKE '{0b40c7cba9aec1c08149d407180b272b37ae28fee2bf5daa9fa07f6da8ed3636}CEPI{0b40c7cba9aec1c08149d407180b272b37ae28fee2bf5daa9fa07f6da8ed3636}'
                            [1] => wpry_posts.post_title LIKE '{0b40c7cba9aec1c08149d407180b272b37ae28fee2bf5daa9fa07f6da8ed3636}Novavax{0b40c7cba9aec1c08149d407180b272b37ae28fee2bf5daa9fa07f6da8ed3636}'
                            [2] => wpry_posts.post_title LIKE '{0b40c7cba9aec1c08149d407180b272b37ae28fee2bf5daa9fa07f6da8ed3636}COVID-19{0b40c7cba9aec1c08149d407180b272b37ae28fee2bf5daa9fa07f6da8ed3636}'
                            [3] => wpry_posts.post_title LIKE '{0b40c7cba9aec1c08149d407180b272b37ae28fee2bf5daa9fa07f6da8ed3636}Vaccine{0b40c7cba9aec1c08149d407180b272b37ae28fee2bf5daa9fa07f6da8ed3636}'
                            [4] => wpry_posts.post_title LIKE '{0b40c7cba9aec1c08149d407180b272b37ae28fee2bf5daa9fa07f6da8ed3636}Funding{0b40c7cba9aec1c08149d407180b272b37ae28fee2bf5daa9fa07f6da8ed3636}'
                            [5] => wpry_posts.post_title LIKE '{0b40c7cba9aec1c08149d407180b272b37ae28fee2bf5daa9fa07f6da8ed3636}Agreement{0b40c7cba9aec1c08149d407180b272b37ae28fee2bf5daa9fa07f6da8ed3636}'
                        )

                )

            [tax_query] => WP_Tax_Query Object
                (
                    [queries] => Array
                        (
                        )

                    [relation] => AND
                    [table_aliases:protected] => Array
                        (
                        )

                    [queried_terms] => Array
                        (
                        )

                    [primary_table] => wpry_posts
                    [primary_id_column] => ID
                )

            [meta_query] => WP_Meta_Query Object
                (
                    [queries] => Array
                        (
                        )

                    [relation] => 
                    [meta_table] => 
                    [meta_id_column] => 
                    [primary_table] => 
                    [primary_id_column] => 
                    [table_aliases:protected] => Array
                        (
                        )

                    [clauses:protected] => Array
                        (
                        )

                    [has_or_relation:protected] => 
                )

            [date_query] => 
            [request] => 
			SELECT DISTINCT   wpry_posts.*
			FROM wpry_posts  INNER JOIN wpry_postmeta AS a ON ( a.post_id = wpry_posts.ID ) LEFT JOIN wpry_postmeta AS b ON ( (( b.post_id = a.post_id )) AND (( b.meta_key LIKE CONCAT( '\_', a.meta_key ) )) ) LEFT JOIN wpry_posts AS c ON ( ( c.post_name = b.meta_value ) AND ( c.post_type = 'acf-field' ) AND (( c.post_content LIKE '%:"text"%' ) OR ( c.post_content LIKE '%:"textarea"%' ) OR ( c.post_content LIKE '%:"wysiwyg"%' ) OR ( c.post_content LIKE '%:"checkbox"%' )) ) 
			WHERE 1=1  AND ( ( ( b.meta_id IS NOT NULL ) AND ( c.ID IS NOT NULL ) AND ( a.meta_value LIKE '%CEPI%' ) AND ( a.meta_value LIKE '%-%' ) AND ( a.meta_value LIKE '%Novavax,%' ) AND ( a.meta_value LIKE '%COVID-19%' ) AND ( a.meta_value LIKE '%Vaccine%' ) AND ( a.meta_value LIKE '%Funding%' ) AND ( a.meta_value LIKE '%Agreement%' ) ) OR ( ( ( wpry_posts.post_title LIKE '%CEPI%' ) OR ( wpry_posts.post_content LIKE '%CEPI%' ) OR ( wpry_posts.post_excerpt LIKE '%CEPI%' ) ) AND ( ( wpry_posts.post_title LIKE '%-%' ) OR ( wpry_posts.post_content LIKE '%-%' ) OR ( wpry_posts.post_excerpt LIKE '%-%' ) ) AND ( ( wpry_posts.post_title LIKE '%Novavax,%' ) OR ( wpry_posts.post_content LIKE '%Novavax,%' ) OR ( wpry_posts.post_excerpt LIKE '%Novavax,%' ) ) AND ( ( wpry_posts.post_title LIKE '%COVID-19%' ) OR ( wpry_posts.post_content LIKE '%COVID-19%' ) OR ( wpry_posts.post_excerpt LIKE '%COVID-19%' ) ) AND ( ( wpry_posts.post_title LIKE '%Vaccine%' ) OR ( wpry_posts.post_content LIKE '%Vaccine%' ) OR ( wpry_posts.post_excerpt LIKE '%Vaccine%' ) ) AND ( ( wpry_posts.post_title LIKE '%Funding%' ) OR ( wpry_posts.post_content LIKE '%Funding%' ) OR ( wpry_posts.post_excerpt LIKE '%Funding%' ) ) AND ( ( wpry_posts.post_title LIKE '%Agreement%' ) OR ( wpry_posts.post_content LIKE '%Agreement%' ) OR ( wpry_posts.post_excerpt LIKE '%Agreement%' ) ) ) )  AND ((wpry_posts.post_type = 'agreement' AND (wpry_posts.post_status = 'publish' OR wpry_posts.post_status = 'acf-disabled')))
			
			ORDER BY wpry_posts.post_title ASC
			
		
            [posts] => Array
                (
                    [0] => WP_Post Object
                        (
                            [ID] => 2882
                            [post_author] => 6
                            [post_date] => 2021-05-14 14:03:29
                            [post_date_gmt] => 2021-05-14 14:03:29
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-09-15 11:58:31
                            [post_modified_gmt] => 2021-09-15 11:58:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=2882
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                )

            [post_count] => 1
            [current_post] => -1
            [in_the_loop] => 
            [post] => WP_Post Object
                (
                    [ID] => 2882
                    [post_author] => 6
                    [post_date] => 2021-05-14 14:03:29
                    [post_date_gmt] => 2021-05-14 14:03:29
                    [post_content] => 
                    [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-09-15 11:58:31
                    [post_modified_gmt] => 2021-09-15 11:58:31
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=agreement&p=2882
                    [menu_order] => 0
                    [post_type] => agreement
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [comment_count] => 0
            [current_comment] => -1
            [found_posts] => 1
            [max_num_pages] => 0
            [max_num_comment_pages] => 0
            [is_single] => 
            [is_preview] => 
            [is_page] => 
            [is_archive] => 1
            [is_date] => 
            [is_year] => 
            [is_month] => 
            [is_day] => 
            [is_time] => 
            [is_author] => 
            [is_category] => 
            [is_tag] => 
            [is_tax] => 
            [is_search] => 1
            [is_feed] => 
            [is_comment_feed] => 
            [is_trackback] => 
            [is_home] => 
            [is_privacy_policy] => 
            [is_404] => 
            [is_embed] => 
            [is_paged] => 
            [is_admin] => 
            [is_attachment] => 
            [is_singular] => 
            [is_robots] => 
            [is_favicon] => 
            [is_posts_page] => 
            [is_post_type_archive] => 1
            [query_vars_hash:WP_Query:private] => 7d1f83bc82f10e9a520c150970868f96
            [query_vars_changed:WP_Query:private] => 1
            [thumbnails_cached] => 
            [stopwords:WP_Query:private] => Array
                (
                    [0] => about
                    [1] => an
                    [2] => are
                    [3] => as
                    [4] => at
                    [5] => be
                    [6] => by
                    [7] => com
                    [8] => for
                    [9] => from
                    [10] => how
                    [11] => in
                    [12] => is
                    [13] => it
                    [14] => of
                    [15] => on
                    [16] => or
                    [17] => that
                    [18] => the
                    [19] => this
                    [20] => to
                    [21] => was
                    [22] => what
                    [23] => when
                    [24] => where
                    [25] => who
                    [26] => will
                    [27] => with
                    [28] => www
                )

            [compat_fields:WP_Query:private] => Array
                (
                    [0] => query_vars_hash
                    [1] => query_vars_changed
                )

            [compat_methods:WP_Query:private] => Array
                (
                    [0] => init_query_flags
                    [1] => parse_tax_query
                )

        )

    [text_provision_q_rslts] => WP_Query Object
        (
            [query] => Array
                (
                    [post_type] => provision_document
                    [posts_per_page] => -1
                    [s] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                )

            [query_vars] => Array
                (
                    [post_type] => provision_document
                    [posts_per_page] => -1
                    [s] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                    [error] => 
                    [m] => 
                    [p] => 0
                    [post_parent] => 
                    [subpost] => 
                    [subpost_id] => 
                    [attachment] => 
                    [attachment_id] => 0
                    [name] => 
                    [pagename] => 
                    [page_id] => 0
                    [second] => 
                    [minute] => 
                    [hour] => 
                    [day] => 0
                    [monthnum] => 0
                    [year] => 0
                    [w] => 0
                    [category_name] => 
                    [tag] => 
                    [cat] => 
                    [tag_id] => 
                    [author] => 
                    [author_name] => 
                    [feed] => 
                    [tb] => 
                    [paged] => 0
                    [meta_key] => 
                    [meta_value] => 
                    [preview] => 
                    [sentence] => 
                    [title] => 
                    [fields] => 
                    [menu_order] => 
                    [embed] => 
                    [category__in] => Array
                        (
                        )

                    [category__not_in] => Array
                        (
                        )

                    [category__and] => Array
                        (
                        )

                    [post__in] => Array
                        (
                        )

                    [post__not_in] => Array
                        (
                        )

                    [post_name__in] => Array
                        (
                        )

                    [tag__in] => Array
                        (
                        )

                    [tag__not_in] => Array
                        (
                        )

                    [tag__and] => Array
                        (
                        )

                    [tag_slug__in] => Array
                        (
                        )

                    [tag_slug__and] => Array
                        (
                        )

                    [post_parent__in] => Array
                        (
                        )

                    [post_parent__not_in] => Array
                        (
                        )

                    [author__in] => Array
                        (
                        )

                    [author__not_in] => Array
                        (
                        )

                    [suppress_filters] => 
                    [ignore_sticky_posts] => 
                    [cache_results] => 1
                    [update_post_term_cache] => 1
                    [lazy_load_term_meta] => 1
                    [update_post_meta_cache] => 1
                    [nopaging] => 1
                    [comments_per_page] => 50
                    [no_found_rows] => 
                    [search_terms_count] => 7
                    [search_terms] => Array
                        (
                            [0] => CEPI
                            [1] => Novavax
                            [2] => COVID-19
                            [3] => Vaccine
                            [4] => Funding
                            [5] => Agreement
                        )

                    [search_orderby_title] => Array
                        (
                            [0] => wpry_posts.post_title LIKE '{0b40c7cba9aec1c08149d407180b272b37ae28fee2bf5daa9fa07f6da8ed3636}CEPI{0b40c7cba9aec1c08149d407180b272b37ae28fee2bf5daa9fa07f6da8ed3636}'
                            [1] => wpry_posts.post_title LIKE '{0b40c7cba9aec1c08149d407180b272b37ae28fee2bf5daa9fa07f6da8ed3636}Novavax{0b40c7cba9aec1c08149d407180b272b37ae28fee2bf5daa9fa07f6da8ed3636}'
                            [2] => wpry_posts.post_title LIKE '{0b40c7cba9aec1c08149d407180b272b37ae28fee2bf5daa9fa07f6da8ed3636}COVID-19{0b40c7cba9aec1c08149d407180b272b37ae28fee2bf5daa9fa07f6da8ed3636}'
                            [3] => wpry_posts.post_title LIKE '{0b40c7cba9aec1c08149d407180b272b37ae28fee2bf5daa9fa07f6da8ed3636}Vaccine{0b40c7cba9aec1c08149d407180b272b37ae28fee2bf5daa9fa07f6da8ed3636}'
                            [4] => wpry_posts.post_title LIKE '{0b40c7cba9aec1c08149d407180b272b37ae28fee2bf5daa9fa07f6da8ed3636}Funding{0b40c7cba9aec1c08149d407180b272b37ae28fee2bf5daa9fa07f6da8ed3636}'
                            [5] => wpry_posts.post_title LIKE '{0b40c7cba9aec1c08149d407180b272b37ae28fee2bf5daa9fa07f6da8ed3636}Agreement{0b40c7cba9aec1c08149d407180b272b37ae28fee2bf5daa9fa07f6da8ed3636}'
                        )

                    [order] => DESC
                )

            [tax_query] => WP_Tax_Query Object
                (
                    [queries] => Array
                        (
                        )

                    [relation] => AND
                    [table_aliases:protected] => Array
                        (
                        )

                    [queried_terms] => Array
                        (
                        )

                    [primary_table] => wpry_posts
                    [primary_id_column] => ID
                )

            [meta_query] => WP_Meta_Query Object
                (
                    [queries] => Array
                        (
                        )

                    [relation] => 
                    [meta_table] => 
                    [meta_id_column] => 
                    [primary_table] => 
                    [primary_id_column] => 
                    [table_aliases:protected] => Array
                        (
                        )

                    [clauses:protected] => Array
                        (
                        )

                    [has_or_relation:protected] => 
                )

            [date_query] => 
            [request] => 
			SELECT DISTINCT   wpry_posts.*
			FROM wpry_posts  INNER JOIN wpry_postmeta AS a ON ( a.post_id = wpry_posts.ID ) LEFT JOIN wpry_postmeta AS b ON ( (( b.post_id = a.post_id )) AND (( b.meta_key LIKE CONCAT( '\_', a.meta_key ) )) ) LEFT JOIN wpry_posts AS c ON ( ( c.post_name = b.meta_value ) AND ( c.post_type = 'acf-field' ) AND (( c.post_content LIKE '%:"text"%' ) OR ( c.post_content LIKE '%:"textarea"%' ) OR ( c.post_content LIKE '%:"wysiwyg"%' ) OR ( c.post_content LIKE '%:"checkbox"%' )) ) 
			WHERE 1=1  AND ( ( ( b.meta_id IS NOT NULL ) AND ( c.ID IS NOT NULL ) AND ( a.meta_value LIKE '%CEPI%' ) AND ( a.meta_value LIKE '%-%' ) AND ( a.meta_value LIKE '%Novavax,%' ) AND ( a.meta_value LIKE '%COVID-19%' ) AND ( a.meta_value LIKE '%Vaccine%' ) AND ( a.meta_value LIKE '%Funding%' ) AND ( a.meta_value LIKE '%Agreement%' ) ) OR ( ( ( wpry_posts.post_title LIKE '%CEPI%' ) OR ( wpry_posts.post_content LIKE '%CEPI%' ) OR ( wpry_posts.post_excerpt LIKE '%CEPI%' ) ) AND ( ( wpry_posts.post_title LIKE '%-%' ) OR ( wpry_posts.post_content LIKE '%-%' ) OR ( wpry_posts.post_excerpt LIKE '%-%' ) ) AND ( ( wpry_posts.post_title LIKE '%Novavax,%' ) OR ( wpry_posts.post_content LIKE '%Novavax,%' ) OR ( wpry_posts.post_excerpt LIKE '%Novavax,%' ) ) AND ( ( wpry_posts.post_title LIKE '%COVID-19%' ) OR ( wpry_posts.post_content LIKE '%COVID-19%' ) OR ( wpry_posts.post_excerpt LIKE '%COVID-19%' ) ) AND ( ( wpry_posts.post_title LIKE '%Vaccine%' ) OR ( wpry_posts.post_content LIKE '%Vaccine%' ) OR ( wpry_posts.post_excerpt LIKE '%Vaccine%' ) ) AND ( ( wpry_posts.post_title LIKE '%Funding%' ) OR ( wpry_posts.post_content LIKE '%Funding%' ) OR ( wpry_posts.post_excerpt LIKE '%Funding%' ) ) AND ( ( wpry_posts.post_title LIKE '%Agreement%' ) OR ( wpry_posts.post_content LIKE '%Agreement%' ) OR ( wpry_posts.post_excerpt LIKE '%Agreement%' ) ) ) )  AND ((wpry_posts.post_type = 'provision_document' AND (wpry_posts.post_status = 'publish' OR wpry_posts.post_status = 'acf-disabled')))
			
			ORDER BY (CASE WHEN wpry_posts.post_title LIKE '{0b40c7cba9aec1c08149d407180b272b37ae28fee2bf5daa9fa07f6da8ed3636}CEPI{0b40c7cba9aec1c08149d407180b272b37ae28fee2bf5daa9fa07f6da8ed3636}' AND wpry_posts.post_title LIKE '{0b40c7cba9aec1c08149d407180b272b37ae28fee2bf5daa9fa07f6da8ed3636}Novavax{0b40c7cba9aec1c08149d407180b272b37ae28fee2bf5daa9fa07f6da8ed3636}' AND wpry_posts.post_title LIKE '{0b40c7cba9aec1c08149d407180b272b37ae28fee2bf5daa9fa07f6da8ed3636}COVID-19{0b40c7cba9aec1c08149d407180b272b37ae28fee2bf5daa9fa07f6da8ed3636}' AND wpry_posts.post_title LIKE '{0b40c7cba9aec1c08149d407180b272b37ae28fee2bf5daa9fa07f6da8ed3636}Vaccine{0b40c7cba9aec1c08149d407180b272b37ae28fee2bf5daa9fa07f6da8ed3636}' AND wpry_posts.post_title LIKE '{0b40c7cba9aec1c08149d407180b272b37ae28fee2bf5daa9fa07f6da8ed3636}Funding{0b40c7cba9aec1c08149d407180b272b37ae28fee2bf5daa9fa07f6da8ed3636}' AND wpry_posts.post_title LIKE '{0b40c7cba9aec1c08149d407180b272b37ae28fee2bf5daa9fa07f6da8ed3636}Agreement{0b40c7cba9aec1c08149d407180b272b37ae28fee2bf5daa9fa07f6da8ed3636}' THEN 2 WHEN wpry_posts.post_title LIKE '{0b40c7cba9aec1c08149d407180b272b37ae28fee2bf5daa9fa07f6da8ed3636}CEPI{0b40c7cba9aec1c08149d407180b272b37ae28fee2bf5daa9fa07f6da8ed3636}' OR wpry_posts.post_title LIKE '{0b40c7cba9aec1c08149d407180b272b37ae28fee2bf5daa9fa07f6da8ed3636}Novavax{0b40c7cba9aec1c08149d407180b272b37ae28fee2bf5daa9fa07f6da8ed3636}' OR wpry_posts.post_title LIKE '{0b40c7cba9aec1c08149d407180b272b37ae28fee2bf5daa9fa07f6da8ed3636}COVID-19{0b40c7cba9aec1c08149d407180b272b37ae28fee2bf5daa9fa07f6da8ed3636}' OR wpry_posts.post_title LIKE '{0b40c7cba9aec1c08149d407180b272b37ae28fee2bf5daa9fa07f6da8ed3636}Vaccine{0b40c7cba9aec1c08149d407180b272b37ae28fee2bf5daa9fa07f6da8ed3636}' OR wpry_posts.post_title LIKE '{0b40c7cba9aec1c08149d407180b272b37ae28fee2bf5daa9fa07f6da8ed3636}Funding{0b40c7cba9aec1c08149d407180b272b37ae28fee2bf5daa9fa07f6da8ed3636}' OR wpry_posts.post_title LIKE '{0b40c7cba9aec1c08149d407180b272b37ae28fee2bf5daa9fa07f6da8ed3636}Agreement{0b40c7cba9aec1c08149d407180b272b37ae28fee2bf5daa9fa07f6da8ed3636}' THEN 3 ELSE 6 END), wpry_posts.post_date DESC
			
		
            [posts] => Array
                (
                    [0] => WP_Post Object
                        (
                            [ID] => 4205
                            [post_author] => 5
                            [post_date] => 2022-02-28 15:24:19
                            [post_date_gmt] => 2022-02-28 15:24:19
                            [post_content] => 
                            [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-02-28 15:24:19
                            [post_modified_gmt] => 2022-02-28 15:24:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4205
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [1] => WP_Post Object
                        (
                            [ID] => 4204
                            [post_author] => 5
                            [post_date] => 2022-02-28 14:53:11
                            [post_date_gmt] => 2022-02-28 14:53:11
                            [post_content] => 
                            [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-02-28 14:53:11
                            [post_modified_gmt] => 2022-02-28 14:53:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4204
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [2] => WP_Post Object
                        (
                            [ID] => 4201
                            [post_author] => 5
                            [post_date] => 2022-02-28 13:33:22
                            [post_date_gmt] => 2022-02-28 13:33:22
                            [post_content] => 
                            [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-02-28 14:46:09
                            [post_modified_gmt] => 2022-02-28 14:46:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4201
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [3] => WP_Post Object
                        (
                            [ID] => 4200
                            [post_author] => 5
                            [post_date] => 2022-02-28 13:13:29
                            [post_date_gmt] => 2022-02-28 13:13:29
                            [post_content] => 
                            [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-03-08 13:54:57
                            [post_modified_gmt] => 2022-03-08 13:54:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4200
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [4] => WP_Post Object
                        (
                            [ID] => 3493
                            [post_author] => 5
                            [post_date] => 2021-08-10 11:15:39
                            [post_date_gmt] => 2021-08-10 11:15:39
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-02-28 08:24:35
                            [post_modified_gmt] => 2022-02-28 08:24:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3493
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [5] => WP_Post Object
                        (
                            [ID] => 2909
                            [post_author] => 6
                            [post_date] => 2021-05-19 15:13:58
                            [post_date_gmt] => 2021-05-19 15:13:58
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-02-28 08:35:40
                            [post_modified_gmt] => 2022-02-28 08:35:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2909
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [6] => WP_Post Object
                        (
                            [ID] => 2908
                            [post_author] => 6
                            [post_date] => 2021-05-19 15:08:05
                            [post_date_gmt] => 2021-05-19 15:08:05
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-02-28 08:59:23
                            [post_modified_gmt] => 2022-02-28 08:59:23
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2908
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [7] => WP_Post Object
                        (
                            [ID] => 2907
                            [post_author] => 6
                            [post_date] => 2021-05-19 14:46:20
                            [post_date_gmt] => 2021-05-19 14:46:20
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-02-28 09:05:23
                            [post_modified_gmt] => 2022-02-28 09:05:23
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2907
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [8] => WP_Post Object
                        (
                            [ID] => 2893
                            [post_author] => 6
                            [post_date] => 2021-05-19 14:40:45
                            [post_date_gmt] => 2021-05-19 14:40:45
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-02-28 09:23:17
                            [post_modified_gmt] => 2022-02-28 09:23:17
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2893
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [9] => WP_Post Object
                        (
                            [ID] => 2892
                            [post_author] => 6
                            [post_date] => 2021-05-14 19:30:23
                            [post_date_gmt] => 2021-05-14 19:30:23
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-06 10:16:05
                            [post_modified_gmt] => 2022-07-06 10:16:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2892
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [10] => WP_Post Object
                        (
                            [ID] => 2890
                            [post_author] => 6
                            [post_date] => 2021-05-14 19:14:07
                            [post_date_gmt] => 2021-05-14 19:14:07
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-06-30 11:32:10
                            [post_modified_gmt] => 2022-06-30 11:32:10
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2890
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [11] => WP_Post Object
                        (
                            [ID] => 2889
                            [post_author] => 6
                            [post_date] => 2021-05-14 19:09:07
                            [post_date_gmt] => 2021-05-14 19:09:07
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-02-28 10:58:28
                            [post_modified_gmt] => 2022-02-28 10:58:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2889
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [12] => WP_Post Object
                        (
                            [ID] => 2885
                            [post_author] => 5
                            [post_date] => 2021-05-14 18:17:37
                            [post_date_gmt] => 2021-05-14 18:17:37
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-13 10:49:07
                            [post_modified_gmt] => 2022-07-13 10:49:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2885
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [13] => WP_Post Object
                        (
                            [ID] => 4661
                            [post_author] => 5
                            [post_date] => 2022-04-20 08:13:06
                            [post_date_gmt] => 2022-04-20 08:13:06
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-04-20 08:13:06
                            [post_modified_gmt] => 2022-04-20 08:13:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4661
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [14] => WP_Post Object
                        (
                            [ID] => 4147
                            [post_author] => 5
                            [post_date] => 2022-04-18 12:53:51
                            [post_date_gmt] => 2022-04-18 12:53:51
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-04-18 13:22:54
                            [post_modified_gmt] => 2022-04-18 13:22:54
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4147
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [15] => WP_Post Object
                        (
                            [ID] => 4148
                            [post_author] => 5
                            [post_date] => 2022-04-12 08:59:45
                            [post_date_gmt] => 2022-04-12 08:59:45
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-06 10:11:50
                            [post_modified_gmt] => 2022-07-06 10:11:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4148
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [16] => WP_Post Object
                        (
                            [ID] => 4161
                            [post_author] => 5
                            [post_date] => 2022-02-02 13:48:58
                            [post_date_gmt] => 2022-02-02 13:48:58
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-04-18 13:17:00
                            [post_modified_gmt] => 2022-04-18 13:17:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4161
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [17] => WP_Post Object
                        (
                            [ID] => 4159
                            [post_author] => 5
                            [post_date] => 2022-02-02 13:10:48
                            [post_date_gmt] => 2022-02-02 13:10:48
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-04-18 13:16:05
                            [post_modified_gmt] => 2022-04-18 13:16:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4159
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [18] => WP_Post Object
                        (
                            [ID] => 4158
                            [post_author] => 5
                            [post_date] => 2022-02-02 13:00:08
                            [post_date_gmt] => 2022-02-02 13:00:08
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-04-18 13:15:30
                            [post_modified_gmt] => 2022-04-18 13:15:30
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4158
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [19] => WP_Post Object
                        (
                            [ID] => 4157
                            [post_author] => 5
                            [post_date] => 2022-02-02 12:54:56
                            [post_date_gmt] => 2022-02-02 12:54:56
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-04-18 13:13:37
                            [post_modified_gmt] => 2022-04-18 13:13:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4157
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [20] => WP_Post Object
                        (
                            [ID] => 4156
                            [post_author] => 5
                            [post_date] => 2022-02-02 12:36:42
                            [post_date_gmt] => 2022-02-02 12:36:42
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-04-18 13:12:51
                            [post_modified_gmt] => 2022-04-18 13:12:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4156
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [21] => WP_Post Object
                        (
                            [ID] => 4155
                            [post_author] => 5
                            [post_date] => 2022-02-02 12:19:16
                            [post_date_gmt] => 2022-02-02 12:19:16
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-04-18 13:12:26
                            [post_modified_gmt] => 2022-04-18 13:12:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4155
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [22] => WP_Post Object
                        (
                            [ID] => 4154
                            [post_author] => 5
                            [post_date] => 2022-02-02 12:13:41
                            [post_date_gmt] => 2022-02-02 12:13:41
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-02-02 12:13:41
                            [post_modified_gmt] => 2022-02-02 12:13:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4154
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [23] => WP_Post Object
                        (
                            [ID] => 4153
                            [post_author] => 5
                            [post_date] => 2022-02-02 12:10:13
                            [post_date_gmt] => 2022-02-02 12:10:13
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-04-18 13:02:30
                            [post_modified_gmt] => 2022-04-18 13:02:30
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4153
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [24] => WP_Post Object
                        (
                            [ID] => 4152
                            [post_author] => 5
                            [post_date] => 2022-02-02 11:51:54
                            [post_date_gmt] => 2022-02-02 11:51:54
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-04-18 13:02:06
                            [post_modified_gmt] => 2022-04-18 13:02:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4152
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [25] => WP_Post Object
                        (
                            [ID] => 4151
                            [post_author] => 5
                            [post_date] => 2022-02-02 11:39:24
                            [post_date_gmt] => 2022-02-02 11:39:24
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-04-18 13:01:35
                            [post_modified_gmt] => 2022-04-18 13:01:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4151
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [26] => WP_Post Object
                        (
                            [ID] => 4150
                            [post_author] => 5
                            [post_date] => 2022-02-02 10:24:30
                            [post_date_gmt] => 2022-02-02 10:24:30
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-04-18 13:01:03
                            [post_modified_gmt] => 2022-04-18 13:01:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4150
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [27] => WP_Post Object
                        (
                            [ID] => 4149
                            [post_author] => 5
                            [post_date] => 2022-02-02 10:15:42
                            [post_date_gmt] => 2022-02-02 10:15:42
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-04-18 13:00:34
                            [post_modified_gmt] => 2022-04-18 13:00:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4149
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [28] => WP_Post Object
                        (
                            [ID] => 4146
                            [post_author] => 5
                            [post_date] => 2022-02-02 07:28:42
                            [post_date_gmt] => 2022-02-02 07:28:42
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-13 09:45:36
                            [post_modified_gmt] => 2022-07-13 09:45:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4146
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [29] => WP_Post Object
                        (
                            [ID] => 3812
                            [post_author] => 5
                            [post_date] => 2021-09-10 12:44:57
                            [post_date_gmt] => 2021-09-10 12:44:57
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-17
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-04-20 09:13:50
                            [post_modified_gmt] => 2022-04-20 09:13:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3812
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [30] => WP_Post Object
                        (
                            [ID] => 3810
                            [post_author] => 5
                            [post_date] => 2021-09-10 12:21:33
                            [post_date_gmt] => 2021-09-10 12:21:33
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-04-20 07:11:54
                            [post_modified_gmt] => 2022-04-20 07:11:54
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3810
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [31] => WP_Post Object
                        (
                            [ID] => 3809
                            [post_author] => 5
                            [post_date] => 2021-09-10 12:11:12
                            [post_date_gmt] => 2021-09-10 12:11:12
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-04-20 09:19:45
                            [post_modified_gmt] => 2022-04-20 09:19:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3809
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [32] => WP_Post Object
                        (
                            [ID] => 3808
                            [post_author] => 5
                            [post_date] => 2021-09-10 11:59:11
                            [post_date_gmt] => 2021-09-10 11:59:11
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-04-20 07:24:05
                            [post_modified_gmt] => 2022-04-20 07:24:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3808
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [33] => WP_Post Object
                        (
                            [ID] => 3807
                            [post_author] => 5
                            [post_date] => 2021-09-10 11:55:25
                            [post_date_gmt] => 2021-09-10 11:55:25
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-04-20 07:42:12
                            [post_modified_gmt] => 2022-04-20 07:42:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3807
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [34] => WP_Post Object
                        (
                            [ID] => 3806
                            [post_author] => 5
                            [post_date] => 2021-09-10 11:47:18
                            [post_date_gmt] => 2021-09-10 11:47:18
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-06 10:17:33
                            [post_modified_gmt] => 2022-07-06 10:17:33
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3806
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [35] => WP_Post Object
                        (
                            [ID] => 3805
                            [post_author] => 5
                            [post_date] => 2021-09-10 11:33:53
                            [post_date_gmt] => 2021-09-10 11:33:53
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-04-20 07:46:59
                            [post_modified_gmt] => 2022-04-20 07:46:59
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3805
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [36] => WP_Post Object
                        (
                            [ID] => 3804
                            [post_author] => 5
                            [post_date] => 2021-09-10 11:20:59
                            [post_date_gmt] => 2021-09-10 11:20:59
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-04-20 07:50:11
                            [post_modified_gmt] => 2022-04-20 07:50:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3804
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [37] => WP_Post Object
                        (
                            [ID] => 3803
                            [post_author] => 5
                            [post_date] => 2021-09-10 10:54:42
                            [post_date_gmt] => 2021-09-10 10:54:42
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-04-20 07:51:06
                            [post_modified_gmt] => 2022-04-20 07:51:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3803
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [38] => WP_Post Object
                        (
                            [ID] => 3802
                            [post_author] => 5
                            [post_date] => 2021-09-10 10:45:57
                            [post_date_gmt] => 2021-09-10 10:45:57
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-04-20 07:54:14
                            [post_modified_gmt] => 2022-04-20 07:54:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3802
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [39] => WP_Post Object
                        (
                            [ID] => 3801
                            [post_author] => 5
                            [post_date] => 2021-09-10 10:36:30
                            [post_date_gmt] => 2021-09-10 10:36:30
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-04-20 08:05:17
                            [post_modified_gmt] => 2022-04-20 08:05:17
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3801
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [40] => WP_Post Object
                        (
                            [ID] => 3799
                            [post_author] => 5
                            [post_date] => 2021-09-10 10:07:18
                            [post_date_gmt] => 2021-09-10 10:07:18
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-04-20 08:44:40
                            [post_modified_gmt] => 2022-04-20 08:44:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3799
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [41] => WP_Post Object
                        (
                            [ID] => 3798
                            [post_author] => 5
                            [post_date] => 2021-09-10 10:02:07
                            [post_date_gmt] => 2021-09-10 10:02:07
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-13 13:35:06
                            [post_modified_gmt] => 2022-07-13 13:35:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3798
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [42] => WP_Post Object
                        (
                            [ID] => 3797
                            [post_author] => 5
                            [post_date] => 2021-09-10 09:54:44
                            [post_date_gmt] => 2021-09-10 09:54:44
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-13 10:57:55
                            [post_modified_gmt] => 2022-07-13 10:57:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3797
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [43] => WP_Post Object
                        (
                            [ID] => 3796
                            [post_author] => 5
                            [post_date] => 2021-09-10 09:03:43
                            [post_date_gmt] => 2021-09-10 09:03:43
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-06-27 13:10:22
                            [post_modified_gmt] => 2022-06-27 13:10:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3796
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                )

            [post_count] => 44
            [current_post] => -1
            [in_the_loop] => 
            [post] => WP_Post Object
                (
                    [ID] => 4205
                    [post_author] => 5
                    [post_date] => 2022-02-28 15:24:19
                    [post_date_gmt] => 2022-02-28 15:24:19
                    [post_content] => 
                    [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-02-28 15:24:19
                    [post_modified_gmt] => 2022-02-28 15:24:19
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4205
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [comment_count] => 0
            [current_comment] => -1
            [found_posts] => 44
            [max_num_pages] => 0
            [max_num_comment_pages] => 0
            [is_single] => 
            [is_preview] => 
            [is_page] => 
            [is_archive] => 1
            [is_date] => 
            [is_year] => 
            [is_month] => 
            [is_day] => 
            [is_time] => 
            [is_author] => 
            [is_category] => 
            [is_tag] => 
            [is_tax] => 
            [is_search] => 1
            [is_feed] => 
            [is_comment_feed] => 
            [is_trackback] => 
            [is_home] => 
            [is_privacy_policy] => 
            [is_404] => 
            [is_embed] => 
            [is_paged] => 
            [is_admin] => 
            [is_attachment] => 
            [is_singular] => 
            [is_robots] => 
            [is_favicon] => 
            [is_posts_page] => 
            [is_post_type_archive] => 1
            [query_vars_hash:WP_Query:private] => 97cc3f5b23383d3be592bf01a0ed574c
            [query_vars_changed:WP_Query:private] => 1
            [thumbnails_cached] => 
            [stopwords:WP_Query:private] => Array
                (
                    [0] => about
                    [1] => an
                    [2] => are
                    [3] => as
                    [4] => at
                    [5] => be
                    [6] => by
                    [7] => com
                    [8] => for
                    [9] => from
                    [10] => how
                    [11] => in
                    [12] => is
                    [13] => it
                    [14] => of
                    [15] => on
                    [16] => or
                    [17] => that
                    [18] => the
                    [19] => this
                    [20] => to
                    [21] => was
                    [22] => what
                    [23] => when
                    [24] => where
                    [25] => who
                    [26] => will
                    [27] => with
                    [28] => www
                )

            [compat_fields:WP_Query:private] => Array
                (
                    [0] => query_vars_hash
                    [1] => query_vars_changed
                )

            [compat_methods:WP_Query:private] => Array
                (
                    [0] => init_query_flags
                    [1] => parse_tax_query
                )

        )

    [provisions] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 4661
                    [post_author] => 5
                    [post_date] => 2022-04-20 08:13:06
                    [post_date_gmt] => 2022-04-20 08:13:06
                    [post_content] => 
                    [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-16
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-04-20 08:13:06
                    [post_modified_gmt] => 2022-04-20 08:13:06
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4661
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [1] => WP_Post Object
                (
                    [ID] => 4147
                    [post_author] => 5
                    [post_date] => 2022-04-18 12:53:51
                    [post_date_gmt] => 2022-04-18 12:53:51
                    [post_content] => 
                    [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-15
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-04-18 13:22:54
                    [post_modified_gmt] => 2022-04-18 13:22:54
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4147
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [2] => WP_Post Object
                (
                    [ID] => 4148
                    [post_author] => 5
                    [post_date] => 2022-04-12 08:59:45
                    [post_date_gmt] => 2022-04-12 08:59:45
                    [post_content] => 
                    [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-07-06 10:11:50
                    [post_modified_gmt] => 2022-07-06 10:11:50
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4148
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [3] => WP_Post Object
                (
                    [ID] => 4205
                    [post_author] => 5
                    [post_date] => 2022-02-28 15:24:19
                    [post_date_gmt] => 2022-02-28 15:24:19
                    [post_content] => 
                    [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-02-28 15:24:19
                    [post_modified_gmt] => 2022-02-28 15:24:19
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4205
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [4] => WP_Post Object
                (
                    [ID] => 4204
                    [post_author] => 5
                    [post_date] => 2022-02-28 14:53:11
                    [post_date_gmt] => 2022-02-28 14:53:11
                    [post_content] => 
                    [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-02-28 14:53:11
                    [post_modified_gmt] => 2022-02-28 14:53:11
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4204
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [5] => WP_Post Object
                (
                    [ID] => 4201
                    [post_author] => 5
                    [post_date] => 2022-02-28 13:33:22
                    [post_date_gmt] => 2022-02-28 13:33:22
                    [post_content] => 
                    [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-02-28 14:46:09
                    [post_modified_gmt] => 2022-02-28 14:46:09
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4201
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [6] => WP_Post Object
                (
                    [ID] => 4200
                    [post_author] => 5
                    [post_date] => 2022-02-28 13:13:29
                    [post_date_gmt] => 2022-02-28 13:13:29
                    [post_content] => 
                    [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-03-08 13:54:57
                    [post_modified_gmt] => 2022-03-08 13:54:57
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4200
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [7] => WP_Post Object
                (
                    [ID] => 4161
                    [post_author] => 5
                    [post_date] => 2022-02-02 13:48:58
                    [post_date_gmt] => 2022-02-02 13:48:58
                    [post_content] => 
                    [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-14
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-04-18 13:17:00
                    [post_modified_gmt] => 2022-04-18 13:17:00
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4161
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [8] => WP_Post Object
                (
                    [ID] => 4159
                    [post_author] => 5
                    [post_date] => 2022-02-02 13:10:48
                    [post_date_gmt] => 2022-02-02 13:10:48
                    [post_content] => 
                    [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-04-18 13:16:05
                    [post_modified_gmt] => 2022-04-18 13:16:05
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4159
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [9] => WP_Post Object
                (
                    [ID] => 4158
                    [post_author] => 5
                    [post_date] => 2022-02-02 13:00:08
                    [post_date_gmt] => 2022-02-02 13:00:08
                    [post_content] => 
                    [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-04-18 13:15:30
                    [post_modified_gmt] => 2022-04-18 13:15:30
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4158
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [10] => WP_Post Object
                (
                    [ID] => 4157
                    [post_author] => 5
                    [post_date] => 2022-02-02 12:54:56
                    [post_date_gmt] => 2022-02-02 12:54:56
                    [post_content] => 
                    [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-04-18 13:13:37
                    [post_modified_gmt] => 2022-04-18 13:13:37
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4157
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [11] => WP_Post Object
                (
                    [ID] => 4156
                    [post_author] => 5
                    [post_date] => 2022-02-02 12:36:42
                    [post_date_gmt] => 2022-02-02 12:36:42
                    [post_content] => 
                    [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-04-18 13:12:51
                    [post_modified_gmt] => 2022-04-18 13:12:51
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4156
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [12] => WP_Post Object
                (
                    [ID] => 4155
                    [post_author] => 5
                    [post_date] => 2022-02-02 12:19:16
                    [post_date_gmt] => 2022-02-02 12:19:16
                    [post_content] => 
                    [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-04-18 13:12:26
                    [post_modified_gmt] => 2022-04-18 13:12:26
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4155
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [13] => WP_Post Object
                (
                    [ID] => 4154
                    [post_author] => 5
                    [post_date] => 2022-02-02 12:13:41
                    [post_date_gmt] => 2022-02-02 12:13:41
                    [post_content] => 
                    [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-02-02 12:13:41
                    [post_modified_gmt] => 2022-02-02 12:13:41
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4154
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [14] => WP_Post Object
                (
                    [ID] => 4153
                    [post_author] => 5
                    [post_date] => 2022-02-02 12:10:13
                    [post_date_gmt] => 2022-02-02 12:10:13
                    [post_content] => 
                    [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-04-18 13:02:30
                    [post_modified_gmt] => 2022-04-18 13:02:30
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4153
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [15] => WP_Post Object
                (
                    [ID] => 4152
                    [post_author] => 5
                    [post_date] => 2022-02-02 11:51:54
                    [post_date_gmt] => 2022-02-02 11:51:54
                    [post_content] => 
                    [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-04-18 13:02:06
                    [post_modified_gmt] => 2022-04-18 13:02:06
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4152
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [16] => WP_Post Object
                (
                    [ID] => 4151
                    [post_author] => 5
                    [post_date] => 2022-02-02 11:39:24
                    [post_date_gmt] => 2022-02-02 11:39:24
                    [post_content] => 
                    [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-04-18 13:01:35
                    [post_modified_gmt] => 2022-04-18 13:01:35
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4151
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [17] => WP_Post Object
                (
                    [ID] => 4150
                    [post_author] => 5
                    [post_date] => 2022-02-02 10:24:30
                    [post_date_gmt] => 2022-02-02 10:24:30
                    [post_content] => 
                    [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-04-18 13:01:03
                    [post_modified_gmt] => 2022-04-18 13:01:03
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4150
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [18] => WP_Post Object
                (
                    [ID] => 4149
                    [post_author] => 5
                    [post_date] => 2022-02-02 10:15:42
                    [post_date_gmt] => 2022-02-02 10:15:42
                    [post_content] => 
                    [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-04-18 13:00:34
                    [post_modified_gmt] => 2022-04-18 13:00:34
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4149
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [19] => WP_Post Object
                (
                    [ID] => 4146
                    [post_author] => 5
                    [post_date] => 2022-02-02 07:28:42
                    [post_date_gmt] => 2022-02-02 07:28:42
                    [post_content] => 
                    [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-07-13 09:45:36
                    [post_modified_gmt] => 2022-07-13 09:45:36
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4146
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [20] => WP_Post Object
                (
                    [ID] => 3812
                    [post_author] => 5
                    [post_date] => 2021-09-10 12:44:57
                    [post_date_gmt] => 2021-09-10 12:44:57
                    [post_content] => 
                    [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-17
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-04-20 09:13:50
                    [post_modified_gmt] => 2022-04-20 09:13:50
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3812
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [21] => WP_Post Object
                (
                    [ID] => 3810
                    [post_author] => 5
                    [post_date] => 2021-09-10 12:21:33
                    [post_date_gmt] => 2021-09-10 12:21:33
                    [post_content] => 
                    [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-15
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-04-20 07:11:54
                    [post_modified_gmt] => 2022-04-20 07:11:54
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3810
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [22] => WP_Post Object
                (
                    [ID] => 3809
                    [post_author] => 5
                    [post_date] => 2021-09-10 12:11:12
                    [post_date_gmt] => 2021-09-10 12:11:12
                    [post_content] => 
                    [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-14
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-04-20 09:19:45
                    [post_modified_gmt] => 2022-04-20 09:19:45
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3809
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [23] => WP_Post Object
                (
                    [ID] => 3808
                    [post_author] => 5
                    [post_date] => 2021-09-10 11:59:11
                    [post_date_gmt] => 2021-09-10 11:59:11
                    [post_content] => 
                    [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-04-20 07:24:05
                    [post_modified_gmt] => 2022-04-20 07:24:05
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3808
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [24] => WP_Post Object
                (
                    [ID] => 3807
                    [post_author] => 5
                    [post_date] => 2021-09-10 11:55:25
                    [post_date_gmt] => 2021-09-10 11:55:25
                    [post_content] => 
                    [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-04-20 07:42:12
                    [post_modified_gmt] => 2022-04-20 07:42:12
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3807
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [25] => WP_Post Object
                (
                    [ID] => 3806
                    [post_author] => 5
                    [post_date] => 2021-09-10 11:47:18
                    [post_date_gmt] => 2021-09-10 11:47:18
                    [post_content] => 
                    [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-07-06 10:17:33
                    [post_modified_gmt] => 2022-07-06 10:17:33
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3806
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [26] => WP_Post Object
                (
                    [ID] => 3805
                    [post_author] => 5
                    [post_date] => 2021-09-10 11:33:53
                    [post_date_gmt] => 2021-09-10 11:33:53
                    [post_content] => 
                    [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-04-20 07:46:59
                    [post_modified_gmt] => 2022-04-20 07:46:59
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3805
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [27] => WP_Post Object
                (
                    [ID] => 3804
                    [post_author] => 5
                    [post_date] => 2021-09-10 11:20:59
                    [post_date_gmt] => 2021-09-10 11:20:59
                    [post_content] => 
                    [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-04-20 07:50:11
                    [post_modified_gmt] => 2022-04-20 07:50:11
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3804
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [28] => WP_Post Object
                (
                    [ID] => 3803
                    [post_author] => 5
                    [post_date] => 2021-09-10 10:54:42
                    [post_date_gmt] => 2021-09-10 10:54:42
                    [post_content] => 
                    [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-04-20 07:51:06
                    [post_modified_gmt] => 2022-04-20 07:51:06
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3803
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [29] => WP_Post Object
                (
                    [ID] => 3802
                    [post_author] => 5
                    [post_date] => 2021-09-10 10:45:57
                    [post_date_gmt] => 2021-09-10 10:45:57
                    [post_content] => 
                    [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-04-20 07:54:14
                    [post_modified_gmt] => 2022-04-20 07:54:14
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3802
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [30] => WP_Post Object
                (
                    [ID] => 3801
                    [post_author] => 5
                    [post_date] => 2021-09-10 10:36:30
                    [post_date_gmt] => 2021-09-10 10:36:30
                    [post_content] => 
                    [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-04-20 08:05:17
                    [post_modified_gmt] => 2022-04-20 08:05:17
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3801
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [31] => WP_Post Object
                (
                    [ID] => 3799
                    [post_author] => 5
                    [post_date] => 2021-09-10 10:07:18
                    [post_date_gmt] => 2021-09-10 10:07:18
                    [post_content] => 
                    [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-04-20 08:44:40
                    [post_modified_gmt] => 2022-04-20 08:44:40
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3799
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [32] => WP_Post Object
                (
                    [ID] => 3798
                    [post_author] => 5
                    [post_date] => 2021-09-10 10:02:07
                    [post_date_gmt] => 2021-09-10 10:02:07
                    [post_content] => 
                    [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-07-13 13:35:06
                    [post_modified_gmt] => 2022-07-13 13:35:06
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3798
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [33] => WP_Post Object
                (
                    [ID] => 3797
                    [post_author] => 5
                    [post_date] => 2021-09-10 09:54:44
                    [post_date_gmt] => 2021-09-10 09:54:44
                    [post_content] => 
                    [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-07-13 10:57:55
                    [post_modified_gmt] => 2022-07-13 10:57:55
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3797
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [34] => WP_Post Object
                (
                    [ID] => 3796
                    [post_author] => 5
                    [post_date] => 2021-09-10 09:03:43
                    [post_date_gmt] => 2021-09-10 09:03:43
                    [post_content] => 
                    [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-06-27 13:10:22
                    [post_modified_gmt] => 2022-06-27 13:10:22
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3796
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [35] => WP_Post Object
                (
                    [ID] => 3493
                    [post_author] => 5
                    [post_date] => 2021-08-10 11:15:39
                    [post_date_gmt] => 2021-08-10 11:15:39
                    [post_content] => 
                    [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-02-28 08:24:35
                    [post_modified_gmt] => 2022-02-28 08:24:35
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3493
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [36] => WP_Post Object
                (
                    [ID] => 2909
                    [post_author] => 6
                    [post_date] => 2021-05-19 15:13:58
                    [post_date_gmt] => 2021-05-19 15:13:58
                    [post_content] => 
                    [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-02-28 08:35:40
                    [post_modified_gmt] => 2022-02-28 08:35:40
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2909
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [37] => WP_Post Object
                (
                    [ID] => 2908
                    [post_author] => 6
                    [post_date] => 2021-05-19 15:08:05
                    [post_date_gmt] => 2021-05-19 15:08:05
                    [post_content] => 
                    [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-02-28 08:59:23
                    [post_modified_gmt] => 2022-02-28 08:59:23
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2908
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [38] => WP_Post Object
                (
                    [ID] => 2907
                    [post_author] => 6
                    [post_date] => 2021-05-19 14:46:20
                    [post_date_gmt] => 2021-05-19 14:46:20
                    [post_content] => 
                    [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-02-28 09:05:23
                    [post_modified_gmt] => 2022-02-28 09:05:23
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2907
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [39] => WP_Post Object
                (
                    [ID] => 2893
                    [post_author] => 6
                    [post_date] => 2021-05-19 14:40:45
                    [post_date_gmt] => 2021-05-19 14:40:45
                    [post_content] => 
                    [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-02-28 09:23:17
                    [post_modified_gmt] => 2022-02-28 09:23:17
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2893
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [40] => WP_Post Object
                (
                    [ID] => 2892
                    [post_author] => 6
                    [post_date] => 2021-05-14 19:30:23
                    [post_date_gmt] => 2021-05-14 19:30:23
                    [post_content] => 
                    [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-07-06 10:16:05
                    [post_modified_gmt] => 2022-07-06 10:16:05
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2892
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [41] => WP_Post Object
                (
                    [ID] => 2890
                    [post_author] => 6
                    [post_date] => 2021-05-14 19:14:07
                    [post_date_gmt] => 2021-05-14 19:14:07
                    [post_content] => 
                    [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-06-30 11:32:10
                    [post_modified_gmt] => 2022-06-30 11:32:10
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2890
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [42] => WP_Post Object
                (
                    [ID] => 2889
                    [post_author] => 6
                    [post_date] => 2021-05-14 19:09:07
                    [post_date_gmt] => 2021-05-14 19:09:07
                    [post_content] => 
                    [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-02-28 10:58:28
                    [post_modified_gmt] => 2022-02-28 10:58:28
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2889
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [43] => WP_Post Object
                (
                    [ID] => 2885
                    [post_author] => 5
                    [post_date] => 2021-05-14 18:17:37
                    [post_date_gmt] => 2021-05-14 18:17:37
                    [post_content] => 
                    [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-07-13 10:49:07
                    [post_modified_gmt] => 2022-07-13 10:49:07
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2885
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

        )

    [invalid_get] => 
    [is_text_search] => 1
    [has_agreement_filters] => 
    [has_any_agreement_filter] => Array
        (
        )

    [found_agreements] => 
    [has_provision_filters] => 
    [found_provisions] => 1
    [lbl_quick_search:GHIAA2019\MapguideSearch:private] => Search results for:
    [lbl_issue:GHIAA2019\MapguideSearch:private] => Issue:
    [lbl_key_term:GHIAA2019\MapguideSearch:private] => Key Term:
    [lbl_agreement_type:GHIAA2019\MapguideSearch:private] => Agreement Type:
    [lbl_partner_type:GHIAA2019\MapguideSearch:private] => Partner Type:
    [lbl_technology:GHIAA2019\MapguideSearch:private] => Technology:
    [lbl_development_stage:GHIAA2019\MapguideSearch:private] => Development Stage:
    [issues_by_id:GHIAA2019\MapguideSearch:private] => Array
        (
            [101] => WP_Term Object
                (
                    [term_id] => 101
                    [name] => Access plans & principles
                    [slug] => equitable-access
                    [term_group] => 0
                    [term_taxonomy_id] => 101
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 19
                    [filter] => raw
                    [parent_name] => Equitable Access
                    [parent_slug] => access-to-medicines
                )

            [100] => WP_Term Object
                (
                    [term_id] => 100
                    [name] => Affordable pricing
                    [slug] => pricing
                    [term_group] => 0
                    [term_taxonomy_id] => 100
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 20
                    [filter] => raw
                    [parent_name] => Equitable Access
                    [parent_slug] => access-to-medicines
                )

            [66] => WP_Term Object
                (
                    [term_id] => 66
                    [name] => Benefit sharing
                    [slug] => benefit-revenue-sharing
                    [term_group] => 0
                    [term_taxonomy_id] => 66
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 8
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [53] => WP_Term Object
                (
                    [term_id] => 53
                    [name] => Business model
                    [slug] => business-model
                    [term_group] => 0
                    [term_taxonomy_id] => 53
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [84] => WP_Term Object
                (
                    [term_id] => 84
                    [name] => Confidentiality
                    [slug] => confidentiality
                    [term_group] => 0
                    [term_taxonomy_id] => 84
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 49
                    [count] => 51
                    [filter] => raw
                    [parent_name] => Protecting & sharing information
                    [parent_slug] => information-sharing
                )

            [271] => WP_Term Object
                (
                    [term_id] => 271
                    [name] => Donation
                    [slug] => donation
                    [term_group] => 0
                    [term_taxonomy_id] => 271
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 5
                    [filter] => raw
                    [parent_name] => Equitable Access
                    [parent_slug] => access-to-medicines
                )

            [72] => WP_Term Object
                (
                    [term_id] => 72
                    [name] => Effects of termination
                    [slug] => effect-of-termination
                    [term_group] => 0
                    [term_taxonomy_id] => 72
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 52
                    [count] => 33
                    [filter] => raw
                    [parent_name] => Term & termination
                    [parent_slug] => term-and-termination
                )

            [281] => WP_Term Object
                (
                    [term_id] => 281
                    [name] => Ensuring continuity
                    [slug] => ensuring-continuity
                    [term_group] => 0
                    [term_taxonomy_id] => 281
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 23
                    [filter] => raw
                    [parent_name] => Equitable Access
                    [parent_slug] => access-to-medicines
                )

            [46] => WP_Term Object
                (
                    [term_id] => 46
                    [name] => Equitable Access
                    [slug] => access-to-medicines
                    [term_group] => 0
                    [term_taxonomy_id] => 46
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [278] => WP_Term Object
                (
                    [term_id] => 278
                    [name] => Governance
                    [slug] => roles-responsibilities
                    [term_group] => 0
                    [term_taxonomy_id] => 278
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 36
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [80] => WP_Term Object
                (
                    [term_id] => 80
                    [name] => Indemnification & liability
                    [slug] => indemnity
                    [term_group] => 0
                    [term_taxonomy_id] => 80
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 50
                    [count] => 52
                    [filter] => raw
                    [parent_name] => Liability
                    [parent_slug] => liability
                )

            [257] => WP_Term Object
                (
                    [term_id] => 257
                    [name] => Information sharing
                    [slug] => information-sharing-information-sharing
                    [term_group] => 0
                    [term_taxonomy_id] => 257
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 49
                    [count] => 42
                    [filter] => raw
                    [parent_name] => Protecting & sharing information
                    [parent_slug] => information-sharing
                )

            [109] => WP_Term Object
                (
                    [term_id] => 109
                    [name] => Insurance
                    [slug] => insurance
                    [term_group] => 0
                    [term_taxonomy_id] => 109
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 50
                    [count] => 24
                    [filter] => raw
                    [parent_name] => Liability
                    [parent_slug] => liability
                )

            [48] => WP_Term Object
                (
                    [term_id] => 48
                    [name] => Intellectual Property
                    [slug] => ip-ownership
                    [term_group] => 0
                    [term_taxonomy_id] => 48
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [50] => WP_Term Object
                (
                    [term_id] => 50
                    [name] => Liability
                    [slug] => liability
                    [term_group] => 0
                    [term_taxonomy_id] => 50
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [88] => WP_Term Object
                (
                    [term_id] => 88
                    [name] => License Grants
                    [slug] => license-grants
                    [term_group] => 0
                    [term_taxonomy_id] => 88
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 55
                    [filter] => raw
                    [parent_name] => Intellectual Property
                    [parent_slug] => ip-ownership
                )

            [87] => WP_Term Object
                (
                    [term_id] => 87
                    [name] => Ownership of IP
                    [slug] => ownership-ip
                    [term_group] => 0
                    [term_taxonomy_id] => 87
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 45
                    [filter] => raw
                    [parent_name] => Intellectual Property
                    [parent_slug] => ip-ownership
                )

            [70] => WP_Term Object
                (
                    [term_id] => 70
                    [name] => Payment Structures
                    [slug] => royalties-and-payments
                    [term_group] => 0
                    [term_taxonomy_id] => 70
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 35
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [102] => WP_Term Object
                (
                    [term_id] => 102
                    [name] => Preparedness & response
                    [slug] => outbreak-preparedness
                    [term_group] => 0
                    [term_taxonomy_id] => 102
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 9
                    [filter] => raw
                    [parent_name] => Equitable Access
                    [parent_slug] => access-to-medicines
                )

            [268] => WP_Term Object
                (
                    [term_id] => 268
                    [name] => Product supply
                    [slug] => supply-purchase-of-products
                    [term_group] => 0
                    [term_taxonomy_id] => 268
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 23
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [49] => WP_Term Object
                (
                    [term_id] => 49
                    [name] => Protecting & sharing information
                    [slug] => information-sharing
                    [term_group] => 0
                    [term_taxonomy_id] => 49
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [90] => WP_Term Object
                (
                    [term_id] => 90
                    [name] => Protection of IP
                    [slug] => protection-results
                    [term_group] => 0
                    [term_taxonomy_id] => 90
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 33
                    [filter] => raw
                    [parent_name] => Intellectual Property
                    [parent_slug] => ip-ownership
                )

            [290] => WP_Term Object
                (
                    [term_id] => 290
                    [name] => Publication of Results
                    [slug] => publication-of-results
                    [term_group] => 0
                    [term_taxonomy_id] => 290
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 49
                    [count] => 28
                    [filter] => raw
                    [parent_name] => Protecting & sharing information
                    [parent_slug] => information-sharing
                )

            [56] => WP_Term Object
                (
                    [term_id] => 56
                    [name] => Regulatory strategy
                    [slug] => regulatory-strategy
                    [term_group] => 0
                    [term_taxonomy_id] => 56
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 28
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [81] => WP_Term Object
                (
                    [term_id] => 81
                    [name] => Representations & Warranties
                    [slug] => warranties
                    [term_group] => 0
                    [term_taxonomy_id] => 81
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 50
                    [count] => 39
                    [filter] => raw
                    [parent_name] => Liability
                    [parent_slug] => liability
                )

            [86] => WP_Term Object
                (
                    [term_id] => 86
                    [name] => Technology transfer
                    [slug] => technology-transfer
                    [term_group] => 0
                    [term_taxonomy_id] => 86
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 49
                    [count] => 19
                    [filter] => raw
                    [parent_name] => Protecting & sharing information
                    [parent_slug] => information-sharing
                )

            [52] => WP_Term Object
                (
                    [term_id] => 52
                    [name] => Term & termination
                    [slug] => term-and-termination
                    [term_group] => 0
                    [term_taxonomy_id] => 52
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [76] => WP_Term Object
                (
                    [term_id] => 76
                    [name] => Term of agreement
                    [slug] => term-of-agreement
                    [term_group] => 0
                    [term_taxonomy_id] => 76
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 52
                    [count] => 37
                    [filter] => raw
                    [parent_name] => Term & termination
                    [parent_slug] => term-and-termination
                )

            [74] => WP_Term Object
                (
                    [term_id] => 74
                    [name] => Termination & withdrawal
                    [slug] => termination-and-withdrawal
                    [term_group] => 0
                    [term_taxonomy_id] => 74
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 52
                    [count] => 36
                    [filter] => raw
                    [parent_name] => Term & termination
                    [parent_slug] => term-and-termination
                )

            [282] => WP_Term Object
                (
                    [term_id] => 282
                    [name] => Territory access commitments
                    [slug] => territory-access-commitments
                    [term_group] => 0
                    [term_taxonomy_id] => 282
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 22
                    [filter] => raw
                    [parent_name] => Equitable Access
                    [parent_slug] => access-to-medicines
                )

        )

    [issues_by_slug:GHIAA2019\MapguideSearch:private] => Array
        (
            [equitable-access] => WP_Term Object
                (
                    [term_id] => 101
                    [name] => Access plans & principles
                    [slug] => equitable-access
                    [term_group] => 0
                    [term_taxonomy_id] => 101
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 19
                    [filter] => raw
                    [parent_name] => Equitable Access
                    [parent_slug] => access-to-medicines
                )

            [pricing] => WP_Term Object
                (
                    [term_id] => 100
                    [name] => Affordable pricing
                    [slug] => pricing
                    [term_group] => 0
                    [term_taxonomy_id] => 100
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 20
                    [filter] => raw
                    [parent_name] => Equitable Access
                    [parent_slug] => access-to-medicines
                )

            [benefit-revenue-sharing] => WP_Term Object
                (
                    [term_id] => 66
                    [name] => Benefit sharing
                    [slug] => benefit-revenue-sharing
                    [term_group] => 0
                    [term_taxonomy_id] => 66
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 8
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [business-model] => WP_Term Object
                (
                    [term_id] => 53
                    [name] => Business model
                    [slug] => business-model
                    [term_group] => 0
                    [term_taxonomy_id] => 53
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [confidentiality] => WP_Term Object
                (
                    [term_id] => 84
                    [name] => Confidentiality
                    [slug] => confidentiality
                    [term_group] => 0
                    [term_taxonomy_id] => 84
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 49
                    [count] => 51
                    [filter] => raw
                    [parent_name] => Protecting & sharing information
                    [parent_slug] => information-sharing
                )

            [donation] => WP_Term Object
                (
                    [term_id] => 271
                    [name] => Donation
                    [slug] => donation
                    [term_group] => 0
                    [term_taxonomy_id] => 271
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 5
                    [filter] => raw
                    [parent_name] => Equitable Access
                    [parent_slug] => access-to-medicines
                )

            [effect-of-termination] => WP_Term Object
                (
                    [term_id] => 72
                    [name] => Effects of termination
                    [slug] => effect-of-termination
                    [term_group] => 0
                    [term_taxonomy_id] => 72
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 52
                    [count] => 33
                    [filter] => raw
                    [parent_name] => Term & termination
                    [parent_slug] => term-and-termination
                )

            [ensuring-continuity] => WP_Term Object
                (
                    [term_id] => 281
                    [name] => Ensuring continuity
                    [slug] => ensuring-continuity
                    [term_group] => 0
                    [term_taxonomy_id] => 281
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 23
                    [filter] => raw
                    [parent_name] => Equitable Access
                    [parent_slug] => access-to-medicines
                )

            [access-to-medicines] => WP_Term Object
                (
                    [term_id] => 46
                    [name] => Equitable Access
                    [slug] => access-to-medicines
                    [term_group] => 0
                    [term_taxonomy_id] => 46
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [roles-responsibilities] => WP_Term Object
                (
                    [term_id] => 278
                    [name] => Governance
                    [slug] => roles-responsibilities
                    [term_group] => 0
                    [term_taxonomy_id] => 278
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 36
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [indemnity] => WP_Term Object
                (
                    [term_id] => 80
                    [name] => Indemnification & liability
                    [slug] => indemnity
                    [term_group] => 0
                    [term_taxonomy_id] => 80
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 50
                    [count] => 52
                    [filter] => raw
                    [parent_name] => Liability
                    [parent_slug] => liability
                )

            [information-sharing-information-sharing] => WP_Term Object
                (
                    [term_id] => 257
                    [name] => Information sharing
                    [slug] => information-sharing-information-sharing
                    [term_group] => 0
                    [term_taxonomy_id] => 257
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 49
                    [count] => 42
                    [filter] => raw
                    [parent_name] => Protecting & sharing information
                    [parent_slug] => information-sharing
                )

            [insurance] => WP_Term Object
                (
                    [term_id] => 109
                    [name] => Insurance
                    [slug] => insurance
                    [term_group] => 0
                    [term_taxonomy_id] => 109
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 50
                    [count] => 24
                    [filter] => raw
                    [parent_name] => Liability
                    [parent_slug] => liability
                )

            [ip-ownership] => WP_Term Object
                (
                    [term_id] => 48
                    [name] => Intellectual Property
                    [slug] => ip-ownership
                    [term_group] => 0
                    [term_taxonomy_id] => 48
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [liability] => WP_Term Object
                (
                    [term_id] => 50
                    [name] => Liability
                    [slug] => liability
                    [term_group] => 0
                    [term_taxonomy_id] => 50
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [license-grants] => WP_Term Object
                (
                    [term_id] => 88
                    [name] => License Grants
                    [slug] => license-grants
                    [term_group] => 0
                    [term_taxonomy_id] => 88
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 55
                    [filter] => raw
                    [parent_name] => Intellectual Property
                    [parent_slug] => ip-ownership
                )

            [ownership-ip] => WP_Term Object
                (
                    [term_id] => 87
                    [name] => Ownership of IP
                    [slug] => ownership-ip
                    [term_group] => 0
                    [term_taxonomy_id] => 87
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 45
                    [filter] => raw
                    [parent_name] => Intellectual Property
                    [parent_slug] => ip-ownership
                )

            [royalties-and-payments] => WP_Term Object
                (
                    [term_id] => 70
                    [name] => Payment Structures
                    [slug] => royalties-and-payments
                    [term_group] => 0
                    [term_taxonomy_id] => 70
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 35
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [outbreak-preparedness] => WP_Term Object
                (
                    [term_id] => 102
                    [name] => Preparedness & response
                    [slug] => outbreak-preparedness
                    [term_group] => 0
                    [term_taxonomy_id] => 102
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 9
                    [filter] => raw
                    [parent_name] => Equitable Access
                    [parent_slug] => access-to-medicines
                )

            [supply-purchase-of-products] => WP_Term Object
                (
                    [term_id] => 268
                    [name] => Product supply
                    [slug] => supply-purchase-of-products
                    [term_group] => 0
                    [term_taxonomy_id] => 268
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 23
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [information-sharing] => WP_Term Object
                (
                    [term_id] => 49
                    [name] => Protecting & sharing information
                    [slug] => information-sharing
                    [term_group] => 0
                    [term_taxonomy_id] => 49
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [protection-results] => WP_Term Object
                (
                    [term_id] => 90
                    [name] => Protection of IP
                    [slug] => protection-results
                    [term_group] => 0
                    [term_taxonomy_id] => 90
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 33
                    [filter] => raw
                    [parent_name] => Intellectual Property
                    [parent_slug] => ip-ownership
                )

            [publication-of-results] => WP_Term Object
                (
                    [term_id] => 290
                    [name] => Publication of Results
                    [slug] => publication-of-results
                    [term_group] => 0
                    [term_taxonomy_id] => 290
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 49
                    [count] => 28
                    [filter] => raw
                    [parent_name] => Protecting & sharing information
                    [parent_slug] => information-sharing
                )

            [regulatory-strategy] => WP_Term Object
                (
                    [term_id] => 56
                    [name] => Regulatory strategy
                    [slug] => regulatory-strategy
                    [term_group] => 0
                    [term_taxonomy_id] => 56
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 28
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [warranties] => WP_Term Object
                (
                    [term_id] => 81
                    [name] => Representations & Warranties
                    [slug] => warranties
                    [term_group] => 0
                    [term_taxonomy_id] => 81
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 50
                    [count] => 39
                    [filter] => raw
                    [parent_name] => Liability
                    [parent_slug] => liability
                )

            [technology-transfer] => WP_Term Object
                (
                    [term_id] => 86
                    [name] => Technology transfer
                    [slug] => technology-transfer
                    [term_group] => 0
                    [term_taxonomy_id] => 86
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 49
                    [count] => 19
                    [filter] => raw
                    [parent_name] => Protecting & sharing information
                    [parent_slug] => information-sharing
                )

            [term-and-termination] => WP_Term Object
                (
                    [term_id] => 52
                    [name] => Term & termination
                    [slug] => term-and-termination
                    [term_group] => 0
                    [term_taxonomy_id] => 52
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [term-of-agreement] => WP_Term Object
                (
                    [term_id] => 76
                    [name] => Term of agreement
                    [slug] => term-of-agreement
                    [term_group] => 0
                    [term_taxonomy_id] => 76
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 52
                    [count] => 37
                    [filter] => raw
                    [parent_name] => Term & termination
                    [parent_slug] => term-and-termination
                )

            [termination-and-withdrawal] => WP_Term Object
                (
                    [term_id] => 74
                    [name] => Termination & withdrawal
                    [slug] => termination-and-withdrawal
                    [term_group] => 0
                    [term_taxonomy_id] => 74
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 52
                    [count] => 36
                    [filter] => raw
                    [parent_name] => Term & termination
                    [parent_slug] => term-and-termination
                )

            [territory-access-commitments] => WP_Term Object
                (
                    [term_id] => 282
                    [name] => Territory access commitments
                    [slug] => territory-access-commitments
                    [term_group] => 0
                    [term_taxonomy_id] => 282
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 22
                    [filter] => raw
                    [parent_name] => Equitable Access
                    [parent_slug] => access-to-medicines
                )

        )

    [filter_issues:GHIAA2019\MapguideSearch:private] => Array
        (
        )

)